Navigation Links
Cryoablation: A New Treatment Option for Some Kidney Tumor Patients

Mayo Clinic researchers report that freezing kidney tumors through percutaneous cryoablation shows promise for patients who are not good candidates// for surgery. Their early findings showing short-term success in more than 90 percent of selected patients are published in this month’s issue of Radiology.

The standard treatment for kidney tumors is surgery, providing a high likelihood of a long-term cure. For some patients, surgery is not an option, and Mayo’s urologists and radiologists collaborated to find alternatives for these individuals. If these patients are frail due to age or illness or are not able to have surgery because of other factors, percutaneous cryoablation may be an option.

“This procedure appears to be a good option for some patients,” says Thomas Atwell, M.D., Mayo Clinic radiologist and the study’s primary investigator. “It makes their hospital stay and recovery time very short and surgical stress is minimal.” He cautions that this procedure is not ideal for everyone, noting that it is an option for only a relatively small subset of patients.

Percutaneous ablation uses needles to penetrate the skin and deliver directly to the tumor either high-intensity, tissue-destroying heat through radiofrequency ablation, or freezing cold through cryoablation. Mayo Clinic’s radiologists are among the most experienced in the world in performing ablation techniques, and have treated nearly 300 kidney tumors either with radiofrequency ablation or cryoablation. Radiofrequency ablation (RFA) burns away the tumor, while cryoablation freezes it.

Mayo Clinic doctors had previous experience with liver tumor cryoablation when they added kidney tumor cryoablation in 2003. Today’s report contains the largest published results for percutaneous cryoablation patients. Mayo researchers report that not only can this technique be an alternative to surgery, but that in some cases, it has benefits over RFA.

Previous ex perience in percutaneous RFA led the researchers to recognize that it has two important limitations. Tumors larger than 3 centimeters are difficult to treat with RFA, with increased rates of technical failures and tumor recurrence. Also, the area being treated cannot be effectively monitored with computed tomography (CT) or ultrasound. The Mayo study findings show that cryoablation can be used for some larger tumors with simultaneous operation of multiple cryoprobes guided by ultrasound. The ablation margin (the edge of the frozen tissue) can be accurately monitored with CT, to ensure that the total tumor mass is treated.

The researchers reviewed the records of the 23 men and 17 women with kidney cancer treated with percutaneous cryoablation at Mayo Clinic between March 12, 2003, and Aug. 4, 2005. They found that this treatment was chosen over RFA for reasons such as larger tumor size, proximity of tumor to ureter or bowel, or a central location on the kidney. Cryoablation was successful in 38 of the 40 patients, with no repeat treatment necessary.

In percutaneous cryoablation, one or more hollow needles are inserted through the skin directly into a tumor. Doctors can observe and guide the insertion by combined use of ultrasound and CT. The needle, or cryoprobe, is filled with argon gas, which results in rapid freezing of the tissue to temperatures of -100° C; and the tissue is then thawed by replacing the argon with helium. The procedure consists of two freezing and thawing cycles, seeking a frozen margin of approximately 5 millimeters beyond the tumor edge to ensure death of the entire tumor. After the cryoprobes are removed, small bandages are placed over the skin puncture sites, and the patient spends one night in the hospital before returning home.

Surgeons continue to seek less invasive methods than the traditional radical nephrectomy (removal of cancerous kidney) for the treatment of small tumors, and percutaneous cryoablat ion is now on the list. With the incidence of kidney cancer steadily increasing over the last 20 years, and the American Cancer Society predicting nearly 52,000 people will be diagnosed this year, with nearly 13,000 dying from it, another option for some patients is good news say the researchers.

“Additional study is still necessary, but we are confident that percutaneous cryoablation will continue to be a good option for some of our patients,” says Bradley Leibovich, M.D., study co-author and Mayo Clinic urologist. “We’ve seen good results in the initial follow-up with these patients, and hope that the long-term results prove this to be a safe alternative for some kidney tumors.” While the researchers caution that they need five to 10 years of follow-up to be able to consider this a curative treatment, they are optimistic about future findings.

Source-Nwswise
SRM
'"/>




Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Focused Treatment For Childhood Cancer
9. Inadequate Drug Treatment For Youth
10. FDA Approves New surgery Treatment for Farsightedness
11. Treatment of antibiotics ineffectual in bronchitis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/24/2017)... ... February 24, 2017 , ... Dr. Ronald E. Hawkins, vice ... appointment of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new ... 10. Dr. Bell comes to Liberty from the Ohio University Heritage College of ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... it is so critically important that we all are aware of our options ... Mediaplanet is proud to announce the launch of its newest edition of "Vision ...
(Date:2/24/2017)... Aliso Viejo, CA (PRWEB) , ... February 24, 2017 , ... ... within Final Cut Pro X . Users have total control over position, rotation, ... amount, and more all within Final Cut Pro X. , With ProGlass Prism users ...
(Date:2/24/2017)... ... 24, 2017 , ... The International Association of Eating Disorders Professionals (iaedp) announces ... See” body image mannequin art competition. Selected from 15 submissions from around the nation, ... at the 31st annual iaedp Symposium, March 22 – 26 in Las Vegas. , ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... services, which specializes in thought leadership , media relations, social media, content ... services that will be powered through Act-On, an intuitive marketing automation platform. , ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 2017  The particle counters market is projected ... USD 275.9 million in 2016, at a CAGR ... http://www.reportlinker.com/p04718602-summary/view-report.html The growing pharmaceutical ... and growth in manufacturing industries in emerging nations ... particle counters. On the other hand, technical limitations ...
(Date:2/23/2017)... 23, 2017 Visiomed, the French leader ... 1997, is changing the landscape of healthcare with ... with pro-active, custom-made solutions. Recognizing the rising demand ... affordable healthcare without walls, Visiomed has launched BewellConnect, ... with healthcare professionals that is empowering the lives ...
(Date:2/23/2017)... 23, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), a ... proprietary products for the urology market, will release financial ... December 31, 2016 before the market open on Thursday, ... host a conference call and webcast to discuss its ... 2017 at 11:00 a.m. Eastern Time (10:00 a.m. Central ...
Breaking Medicine Technology: